Dr. Lenz on Later-Line Combo Approaches in CRC


Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.

Heinz-Josef Lenz, MD, FACP, professor of medicine; J. Terrence Lanni Chair in Gastrointestinal Cancer Research; and co-director of the University of Southern California (USC) Center for Molecular Pathway and Drug Discovery, at the USC Norris Comprehensive Cancer Center, discusses third-line treatment combination approaches in colorectal cancer (CRC).

Beyond the standard-of-care single-agent regorafenib (Stivarga) or single-agent TAS-102 (trifluridine/tipiracil; Lonsurf), very exciting developments with combination therapies in the third-line setting have been reported, says Lenz. One of the most exciting clinical trials presented during the 2019 ASCO Annual Meeting was a trial that examined the use of regorafenib plus nivolumab (Opdivo) in gastric and colon cancer. The data in patients with microsatellite-stable disease showed very promising response rates in CRC, at 36%, and gastric cancer, at 44%. Patients with gastric cancer who were previously progressed on immune-checkpoint inhibitors responded again to regorafenib, indicating that resistance to immune checkpoint therapy can be overcome. 

This is a very important mechanism of action that can be used to better understand the significance of anti-VEGF and immune checkpoint inhibitors are a very important new combination that can be and should be further explored, concludes Lenz.

Related Videos
J. Randolph (Randy) Hecht, MD
Qian (Janie) Qin, MD
Ajai Chari, MD
Joachim G. J. V. Aerts, MD, PhD
Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
J. Randolph (Randy) Hecht, MD
Related Content